PURPOSE: To investigate the prognostic value of systemic exposure to etoposide (Area Under the concentration Curve (AUC(VP16))) on overall survival (OS) in patients with small cell lung cancer (SCLC). PATIENTS AND METHODS: Data from 52 patients with limited stage (n=17) or metastatic (n=35) SCLC were analysed. They received at least two courses of etoposide (120mg/(m(2)day) on 3 days) combined with either doxorubicin-ifosfamide (AVI, n=29) or platinum compounds (carboplatin: n=16; cisplatin: n=7). Population pharmacokinetic-pharmacodynamic (PK-PD) study was performed using NON-linear Mixed Effect Model (NONMEM) and Splus software with univariate and multivariate analyses. RESULTS: Etoposide plasma concentration vs. time was described by a two compartment model. Etoposide clearance (CL) was significantly dependant on serum creatinine (Scr). Ifosfamide (IFO) coadministration increased etoposide clearance by 28% (median CL(VP16): 2.42L/h vs. 1.89L/h, p<0.0005) leading to a reduced systemi
%0 Journal Article
%1 You.2008
%A You, Benoit
%A Tranchand, Brigitte
%A Girard, Pascal
%A Falandry, Claire
%A Ribba, Benjamin
%A Chabaud, Sylvie
%A Souquet, Pierre-Jean
%A Court-Fortune, Isabelle
%A Trillet-Lenoir, Véronique
%A Fournel, Cécile
%A Tod, Michel
%A Freyer, Gilles
%D 2008
%J Lung cancer (Amsterdam, Netherlands)
%K & 80 Adult Aged Aged, Antineoplastic Area Carboplatinadministration Carcinomadrug Cell Chemotherapy Chromatography, Clearance Combined Curve Doxorubicinadministration Estimate Etoposideadministration Female Hazards High Humans Ifosfamideadministration Kaplan-Meiers Liquid Lung Male Mesnaadministration Metabolic Middle Models Neoplasmsdrug Pressure Prognosis Proportional Protocolspharmacokineticstherapeutic Rate Small Under and dosage dosagepharmacokinetics over therapymortality use
%N 2
%P 261-272
%T Etoposide pharmacokinetics and survival in patients with small cell lung cancer: a multicentre study
%V 62
%X PURPOSE: To investigate the prognostic value of systemic exposure to etoposide (Area Under the concentration Curve (AUC(VP16))) on overall survival (OS) in patients with small cell lung cancer (SCLC). PATIENTS AND METHODS: Data from 52 patients with limited stage (n=17) or metastatic (n=35) SCLC were analysed. They received at least two courses of etoposide (120mg/(m(2)day) on 3 days) combined with either doxorubicin-ifosfamide (AVI, n=29) or platinum compounds (carboplatin: n=16; cisplatin: n=7). Population pharmacokinetic-pharmacodynamic (PK-PD) study was performed using NON-linear Mixed Effect Model (NONMEM) and Splus software with univariate and multivariate analyses. RESULTS: Etoposide plasma concentration vs. time was described by a two compartment model. Etoposide clearance (CL) was significantly dependant on serum creatinine (Scr). Ifosfamide (IFO) coadministration increased etoposide clearance by 28% (median CL(VP16): 2.42L/h vs. 1.89L/h, p<0.0005) leading to a reduced systemi
@article{You.2008,
abstract = {PURPOSE: To investigate the prognostic value of systemic exposure to etoposide (Area Under the concentration Curve (AUC(VP16))) on overall survival (OS) in patients with small cell lung cancer (SCLC). PATIENTS AND METHODS: Data from 52 patients with limited stage (n=17) or metastatic (n=35) SCLC were analysed. They received at least two courses of etoposide (120mg/(m(2)day) on 3 days) combined with either doxorubicin-ifosfamide (AVI, n=29) or platinum compounds (carboplatin: n=16; cisplatin: n=7). Population pharmacokinetic-pharmacodynamic (PK-PD) study was performed using NON-linear Mixed Effect Model (NONMEM) and Splus software with univariate and multivariate analyses. RESULTS: Etoposide plasma concentration vs. time was described by a two compartment model. Etoposide clearance (CL) was significantly dependant on serum creatinine (Scr). Ifosfamide (IFO) coadministration increased etoposide clearance by 28% (median CL(VP16): 2.42L/h vs. 1.89L/h, p<0.0005) leading to a reduced systemi},
added-at = {2010-02-04T16:31:48.000+0100},
author = {You, Benoit and Tranchand, Brigitte and Girard, Pascal and Falandry, Claire and Ribba, Benjamin and Chabaud, Sylvie and Souquet, Pierre-Jean and Court-Fortune, Isabelle and Trillet-Lenoir, Véronique and Fournel, Cécile and Tod, Michel and Freyer, Gilles},
biburl = {https://www.bibsonomy.org/bibtex/2a1dea6b817e2247c470badacd57554e5/hruehs},
interhash = {0c2b893dca75b908d638397e8df58ccc},
intrahash = {a1dea6b817e2247c470badacd57554e5},
issn = {0169-5002},
journal = {Lung cancer (Amsterdam, Netherlands)},
keywords = {& 80 Adult Aged Aged, Antineoplastic Area Carboplatinadministration Carcinomadrug Cell Chemotherapy Chromatography, Clearance Combined Curve Doxorubicinadministration Estimate Etoposideadministration Female Hazards High Humans Ifosfamideadministration Kaplan-Meiers Liquid Lung Male Mesnaadministration Metabolic Middle Models Neoplasmsdrug Pressure Prognosis Proportional Protocolspharmacokineticstherapeutic Rate Small Under and dosage dosagepharmacokinetics over therapymortality use},
number = 2,
pages = {261-272},
timestamp = {2010-02-04T16:31:52.000+0100},
title = {Etoposide pharmacokinetics and survival in patients with small cell lung cancer: a multicentre study},
volume = 62,
year = 2008
}